VA
HRMY icon

Vident Advisory’s Harmony Biosciences HRMY Stock Holding History

Vident Advisory’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$872K Sell
23,936
-162
-0.7% -$5.11K 0.01% 1046
2026
Q1 		$675K Buy
24,098
+6,108
+34% +$200K 0.01% 1077
2025
Q4 		$673K Sell
17,990
-267
-1% -$8.78K 0.01% 991
2025
Q3 		$503K Buy
18,257
+2,968
+19% +$102K ﹤0.01% 1202
2025
Q2 		$483K Sell
15,289
-59
-0.4% -$1.9K 0.01% 1076
2025
Q1 		$509K Sell
15,348
-1,078
-7% -$38.6K 0.01% 1022
2024
Q4 		$565K Buy
16,426
+2,493
+18% +$85.7K 0.01% 880
2024
Q3 		$557K Sell
13,933
-7,365
-35% -$259K 0.01% 870
2024
Q2 		$643K Buy
+21,298
New +$640K 0.02% 772
2024
Q1 		– Sell
-6,312
Closed -$204K – 1361
2023
Q4 		$204K Sell
6,312
-5,529
-47% -$154K 0.01% 1208
2023
Q3 		$388K Buy
+11,841
New +$411K 0.01% 787

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vident Advisory's HRMY Position: Q2 2026 in Review

Vident Advisory reduced its Harmony Biosciences (HRMY) stake by 0.67% in Q2 2026, selling an estimated $5.11K and leaving 23,936 shares worth $872K. The position accounts for 0.01% of the portfolio, ranked #1046.

Vident Advisory first reported a position in HRMY in Q3 2023 and has held it in 11 quarters since. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Vident Advisory held 23,936 shares of Harmony Biosciences worth $872K as of Q2 2026.
  • Vident Advisory sold 162 Harmony Biosciences shares in Q2 2026, an estimated $5.11K.
  • Harmony Biosciences made up 0.01% of Vident Advisory's portfolio in Q2 2026, its #1046 holding.
  • Vident Advisory first reported a position in Harmony Biosciences in Q3 2023 and has held it in 11 quarters since.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.